Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia

Psychiatry Research

Volumn 153, Issue 1, 2007, Pages 77-81

  Pae, Chi Un ^a,b   Kim, Tae Suk ^a   Patkar, Ashwin A ^b   Kim, Jung Jin ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Jun, Tae Youn ^a   Lee, Chul ^a   Paik, In Ho ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Korean; Manganese superoxide dismutase; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

ALANINE; CHLORPROMAZINE; CLOZAPINE; DNA; HALOPERIDOL; MANGANESE SUPEROXIDE DISMUTASE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; VALINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ASSAY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KOREA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MNSOD GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALANINE; ALLELES; ANTIPSYCHOTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REFERENCE VALUES; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE; VALINE;

EID: 34548496872     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.04.011     Document Type: Article

References (29)

1. Akyol O., Yanik M., Elyas H., Namli M., Canatan H., Akin H., Yuce H., Yilmaz H.R., Tutkun H., Sogut S., Herken H., Ozyurt H., Savas H.A., and Zoroglu S.S. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 (2005) 123-131
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. (1994), APA, Washington, DC
3. Cavalli-Sforza L. The History and Geography of Human Genes (1994), Princeton University Press, Princeton, NJ
4. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., and Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49 (2004) 205-209
5. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV) (1997), American Psychiatric Press, Washington, DC
6. Freedman R., Leonard S., Olincy A., Kaufmann C.A., Malaspina D., Cloninger C.R., Svrakic D., Faraone S.V., and Tsuang M.T. Evidence for the multigenic inheritance of schizophrenia. American Journal of Medical Genetics 105 (2001) 794-800
7. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised. Department of Health, Education and Welfare (1976), US DHEW Publication, Washington, DC 534-537
8. Hiroi S., Harada H., Nishi H., Satoh M., Nagai R., and Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochemical and Biophysical Research Communications 261 (1999) 332-339
9. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., and Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 23 (2000) 170-177
10. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenia. Psychiatry Research 23 (1988) 99-110
11. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., Sherrington R., Adolfsson R., and Jazin E. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. American Journal of Human Genetics 69 (2001) 96-105
12. Lohr J.B., and Caligiuri M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Journal of Clinical Psychiatry 57 (1996) 167-173
13. Lohr J.B., Kuczenski R., and Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17 (2003) 47-62
14. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research 19 (1996) 1-17
15. Michel T.M., Thome J., Martin D., Nara K., Zwerina S., Tatschner T., Weijers H.G., and Koutsilieri E. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. Journal of Neural Transmission 111 (2004) 1191-1201
16. Pae C.U., Paik I.H., Lee C., Lee S.J., Kim J.J., and Lee C.U. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 50 (2004) 54-56
17. Parikh V., Khan M.M., and Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research 37 (2003) 43-51
18. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., and Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 121 (2003) 109-122
19. Schooler N.R., and Kane J.M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39 (1982) 486-487
20. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawa-Hattori Y., Shimizu Y., and Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochemical and Biophysical Research Communications 226 (1996) 561-565
21. Swartz J.R., Burgoyne K., Smith M., Gadasally R., Ananth J., and Ananth K. Tardive dyskinesia and ethnicity: review of the literature. Annals of Clinical Psychiatry 9 (1997) 53-59
22. Van Landeghem G.F., Tabatabaie P., Kucinskas V., Saha N., and Beckman G. Ethnic variation in the mitochondrial targeting sequence polymorphism of MnSOD. Human Heredity 49 (1999) 190-193
23. Yao J.K., Reddy R., McElhinny L.G., and van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. Journal of Psychiatric Research 32 (1998) 385-391
24. Yao J.K., Reddy R.D., and van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
25. Zhang X., Hou G., Sha W., and Reynolds G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. Journal of Psychiatric Research 36 (2002) 317-324
26. Zhang X.Y., Zhou D.F., Cao L.Y., da Chen C., Zhu F.Y., and Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophrenia Research 62 (2003) 245-250
27. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., and Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Research 117 (2003) 85-88
28. Zhang Z.J., Zhang X.B., Hou G., Yao H., and Reynolds G.P. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatric Genetics 13 (2003) 187-192
29. Zhang X.Y., Zhou D.F., Cao L.Y., Xu C.Q., da Chen C., and Wu G.Y. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology 241 (2004) 83-86